CRISPR Therapeutics AG is a gene editing company focused on developing novel medicines using its proprietary CRISPR/Cas9 platform, aiming to create potentially curative therapies for serious diseases. Operating within the biotechnology sector, the company's primary focus is on ex vivo and in vivo gene-edited therapies, with its lead product, CASGEVY, targeting hemoglobinopathies. The company's pipeline extends to oncology, autoimmune diseases, cardiovascular diseases, and type 1 diabetes, supported by strategic collaborations. In its most recent reported quarters, Q1 2025 saw an EPS of -1.58 against an estimate of -1.27676, and revenue of 865,000.0. This followed Q4 2024, where the company reported an actual EPS of -0.44 against an estimate of -1.18562, with revenue at 35,691,000.0. Comparing the last two reported quarters (Q1 2025 and Q4 2024) to the two prior quarters (Q3 2025 and Q2 2025), there is a trend of decelerating EPS performance, with actual EPS figures becoming more negative, while revenue has seen a significant drop from Q4 2024 to Q1 2025. The company has missed EPS estimates in Q1 2025 and Q3 2025, but beat estimates in Q4 2024 and Q2 2025. Historically, CRISPR Therapeutics has shown a trajectory of increasing revenue, though EPS performance has been consistently negative and below estimates in several periods, indicating ongoing investment in research and development. The company has demonstrated a pattern of revenue growth in earlier periods, but recent quarters show a significant decline in reported revenue. Recent news highlights management presentations at industry conferences, emphasizing the potential of its gene-editing platform and pipeline candidates like CTX310, while acknowledging headwinds from economic conditions and limited revenue from its sole approved drug, Casgevy. Investor interest is noted, with significant positions held by investment funds, underscoring the focus on pipeline progression and Casgevy's market penetration. Looking ahead, investors will watch for updates on the commercial ramp-up of Casgevy and the advancement of the company's broader development programs, particularly the progress of pipeline candidates and their potential impact on future financial performance, as well as the company's ability to meet projected revenue and EPS targets in upcoming quarters.
